Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-167

The CR has been on the longest to see any efficacy on the clinical trial and at a low dosage, not the lowest but still very low, hence IMU saying it's excellent result which @Mason14 even admitted as Ph1 clinical trial primary end point isn't to demonstrate efficacy but safety to allow increase in dosage and see some efficacy at the end of Ph1 and then conduct Ph2 clinical trial at the optimal dosage on a bigger subject to demonstrate efficacy.

@Mason14 know this so for him stating that management increase the dosage as they weren't seeing the efficacy they wanted is clearly misleading and a big red flag to me for what his intention is. Then today his angle is efficacy has been worst in highest dosage but they've been on the shortest treatment timeframe, look at this and tell me CF33 isn't behaving as expected which was what LC has mentioned previously multiple time. The dosage are increased as safety is met on the previous dosage.